Evaluation of the ability of LL-37 to neutralise LPS in vitro and Ex vivo

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Scott, Aaron ^a   Weldon, Sinéad ^a   Buchanan, Paul J ^a   Schock, Bettina ^a   Ernst, Robert K ^b   McAuley, Danny F ^a   Tunney, Michael M ^c   Irwin, Chris R ^a   Elborn, J Stuart ^a   Taggart, Clifford C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEOXYRIBONUCLEASE; DNA; GLYCOSAMINOGLYCAN; HEPARIN LYASE; HEPARINASE II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; ANTITOXIN; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; LIPOPOLYSACCHARIDE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CASE REPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DNA BINDING; EX VIVO STUDY; GLYCOBIOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG PARENCHYMA; MONOCYTE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SIGNAL TRANSDUCTION; SPUTUM ANALYSIS; BIOSYNTHESIS; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; LUNG; METABOLISM; MICROBIOLOGY; TUMOR CELL LINE;

PSEUDOMONAS AERUGINOSA;

ANTI-INFLAMMATORY AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTITOXINS; CELL LINE, TUMOR; CYSTIC FIBROSIS; DNA; GLYCOSAMINOGLYCANS; HUMANS; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; LUNG; MONOCYTES; PSEUDOMONAS AERUGINOSA; SIGNAL TRANSDUCTION;

EID: 80054767602     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026525     Document Type: Article

References (57)

1. Donaldson SH, Boucher RC, (2007) Sodium channels and cystic fibrosis. Chest 132: 1631-1636.
2. Gibson RL, Burns JL, Ramsey BW, (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168: 918-951.
3. Döring G, Gulbins E, (2009) Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol 11: 208-216.
4. Bals R, Weiner DJ, Wilson JM, (1999) The innate immune system in cystic fibrosis lung disease. J Clin Invest 103: 303-307.
5. Hiemstra PS, (2007) The role of epithelial beta-defensins and cathelicidins in host defense of the lung. Exp Lung Res 33: 537-542.
6. Smith JJ, Travis SM, Greenberg EP, Welsh MJ, (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85: 229-236.
7. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, et al. (1997) Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88: 553-560.
8. Bals R, Weiner DJ, Meegalla RL, Accurso F, Wilson JM, (2001) Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol 25: 21-25.
9. Xiao W, Hsu YP, Ishizaka A, Kirikae T, Moss RB, (2005) Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 128: 2316-2326.
10. Chen CI, Schaller-Bals S, Paul KP, Wahn U, Bals R, (2004) Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cyst Fibros 3: 45-50.
11. Bals R, Wang X, Zasloff M, Wilson JM, (1998) The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A 95: 9541-9546.
12. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM, (1999) Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 67: 6084-6089.
13. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI, (1998) Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42: 2206-2214.
14. Dürr UH, Sudheendra US, Ramamoorthy A, (2006) LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758: 1408-1425.
15. Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, et al. (2000) Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 68: 2748-2755.
16. Burton MF, Steel PG, (2009) The chemistry and biology of LL-37. Nat Prod Rep 26: 1572-1584.
17. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, et al. (2008) Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76: 4176-4182.
18. Weiner DJ, Bucki R, Janmey PA, (2003) The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 28: 738-745.
19. Bucki R, Byfield FJ, Janmey PA, (2007) Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J 29: 624-632.
20. Herasimenka Y, Benincasa M, Mattiuzzo M, Cescutti P, Gennaro R, et al. (2005) Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens. Peptides 26: 1127-1132.
21. Benincasa M, Mattiuzzo M, Herasimenka Y, Cescutti P, Rizzo R, et al. (2009) Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens. J Pept Sci 15: 595-600.
22. Felgentreff K, Beisswenger C, Griese M, Gulder T, Bringmann G, et al. (2006) The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 27: 3100-3106.
23. Bucki R, Namiot DB, Namiot Z, Savage PB, Janmey PA, (2008) Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. J Antimicrob Chemother 62: 329-335.
24. Schmidtchen A, Frick IM, Andersson E, Tapper H, Björck L, (2002) Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 46: 157-168.
25. Barañska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A, (2006) Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J Antimicrob Chemother 57: 260-265.
26. Bergsson G, Reeves EP, McNally P, Chotirmall SH, Greene CM, et al. (2009) LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 183: 543-551.
27. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, et al. (2005) Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77: 451-459.
28. Chen C, Brock R, Luh F, Chou PJ, Larrick JW, et al. (1995) The solution structure of the active domain of CAP18-a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett 370: 46-52.
29. Rosenfeld Y, Papo N, Shai Y, (2006) Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem 281: 1636-1643.
30. Nagaoka I, Hirota S, Niyonsaba F, Hirata M, Adachi Y, et al. (2001) Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-α by blocking the binding of LPS to CD14(+) cells. J Immunol 167: 3329-3338.
31. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE, (2002) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 169: 3883-3891.
32. Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, et al. (2006) LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 50: 1672-1679.
33. Pier GB, (2007) Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int J Med Microbiol 297: 277-295.
34. Darveau RP, Hancock RE, (1983) Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol 155: 831-838.
35. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
36. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ, (2000) Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 165: 618-622.
37. Caroff M, Tacken A, Szabó L, (1988) Detergent-accelerated hydrolysis of bacterial endotoxins and determination of the anomeric configuration of the glycosyl phosphate present in the "isolated lipid A" fragment of the Bordetella pertusis endotoxin. Carbo Res 175: 273-282.
38. Hajjar AM, Harvey MD, Shaffer SA, Goodlett DR, Sjöstedt A, et al. (2006) Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors. Infect Immun 74: 6730-6738.
39. Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey, et al. (2007) Unique lipid A modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J Infect Dis 196: 1088-1092.
40. Taggart CC, Greene CM, McElvaney NG, O'Neill S, (2002) Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IκBα degradation without affecting phosphorylation or ubiquitination. J Biol Chem 277: 33648-33653.
41. Chakraborty K, Maity PC, Sil AK, Takeda Y, Das S, (2009) cAMP stringently regulates human cathelicidin antimicrobial peptide expression in the mucosal epithelial cells by activating cAMP-response element-binding protein, AP-1, and inducible cAMP early repressor. J Biol Chem 284: 21810-21827.
42. Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, et al. (2009) Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 183: 8148-8156.
43. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176: 2455-2464.
44. Ernst RK, Yi EC, Guo L, Lim KB, Burns JL, et al. (1999) Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286: 1561-1565.
45. Cigana C, Curcurù L, Leone MR, Ieranò T, Lorè NI, et al. (2009) Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection. PLoS One 4: e8439 doi:10.1371/journal.pone.0008439.
46. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI, (2002) Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 3: 354-359.
47. Ernst RK, Hajjar AM, Tsai JH, Moskowitz SM, Wilson CB, et al. (2003) Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4. J Endotoxin Res 29: 395-400.
48. Solic N, Wilson J, Wilson SJ, Shute JK, (2005) Endothelial activation and increased heparan sulfate expression in cystic fibrosis. Am J Respir Crit Care Med 172: 892-898.
49. Rahmoune H, Lamblin G, Lafitte JJ, Galabert C, Filliat M, et al. (1991) Chondroitin sulfate in sputum from patients with cystic fibrosis and chronic bronchitis. Am J Respir Cell Mol Biol 5: 315-320.
50. Shriver Z, Hu Y, Pojasek K, Sasisekharan R, (1998) Heparinase II from Flavobacterium heparinum. Role of cysteine in enzymatic activity as probed by chemical modification and site- directed mutagenesis. J Biol Chem 273: 22904-22912.
51. Rosenfeld Y, Shai Y, (2006) Lipopolysaccharide (endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta 1758: 1513-1522.
52. Meyer KC, Sharma A, (1997) Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 156: 1536-1540.
53. Lethem MI, James SL, Marriott C, Burke JF, (1990) The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J 3: 19-23.
54. Hilliard TN, Regamey N, Shute JK, Nicholson AG, Alton EW, et al. (2007) Airway remodelling in children with cystic fibrosis. Thorax 62: 1074-1080.
55. Bhaskar KR, Turner BS, Grubman SA, Jefferson DM, LaMont JT, (1998) Dysregulation of proteoglycan production by intrahepatic biliary epithelial cells bearing defective (delta-f508) cystic fibrosis transmembrane conductance regulator. Hepatology 27: 7-14.
56. Papakonstantinou E, Karakiulakis G, (2009) The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance. Br J Pharmacol 157: 1111-1127.
57. Baugh RF, Deemar KA, Zimmermann JJ, (1992) Heparinase in the activated clotting time assay: monitoring heparin-independent alterations in coagulation function. Anesth Analg 74: 201-205.